Broadwood Urges STAAR Shareholders to Reject Alcon Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy ALC?
Source: Newsfilter
- Shareholder Opposition: Broadwood Partners, holding 30.2% of STAAR's shares, strongly opposes the acquisition by Alcon, deeming the deal ill-conceived and detrimental to the company's future prospects.
- Special Meeting Postponement: The Special Meeting originally scheduled for October 23, 2025, has been postponed to January 6, 2026, reflecting ongoing shareholder skepticism and dissatisfaction regarding the transaction.
- Shareholder Rights Emphasis: Broadwood insists that shareholders should have the final say, urging them to vote against the proposed transaction at the upcoming meeting to protect the company's interests.
- Management Scrutiny: Broadwood highlights that STAAR and Alcon have failed to convincingly advocate for the deal, raising widespread concerns about the timing and pricing, which could impact the company's governance structure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise
13 Analyst Rating
7 Buy
5 Hold
1 Sell
Moderate Buy
Current: 78.550
Low
78.17
Averages
93.73
High
117.26
Current: 78.550
Low
78.17
Averages
93.73
High
117.26
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bullish Investment Thesis on Alcon Inc.
- Market Leadership: Alcon Inc. is the world's largest pure-play eye care device company, with its global vision care market share projected to increase from 11.7% in 2020 to 13.5% in 2024, showcasing its competitive edge in a $35 billion market and bolstering investor confidence.
- Profitability Enhancement: The Surgical segment generates approximately 60% of EBIT, leveraging strong brand leadership and high-margin consumables, with operating margins expected to rise to 20-25%, providing long-term visibility into future cash flows.
- Innovation Platform Rollout: The multi-year rollout of the new UNITY surgical platform aims to replace existing equipment and enhance hospital efficiency; despite execution risks, the market has yet to fully recognize its potential for a ~7% revenue CAGR.
- Investment Appeal: Although Alcon's stock price has depreciated by about 8.66% since last year, the valuation framework suggests a price range of $65 to $138 based on a 20x P/E multiple, indicating significant upside potential that has attracted interest from 41 hedge funds.
See More
Alcon Launches PRECISION7 Contact Lenses in Canada
- Product Innovation: The PRECISION7 contact lens features the world's first ACTIV-FLO system, providing up to 16 hours of comfort and clear vision even on day seven, thereby addressing the need for extended wear options in the market.
- Market Demand: While nearly 90% of eye care professionals believe daily disposables are better for patients, over half of new patients still opt for reusable lenses; the launch of PRECISION7 fills this gap by offering an affordable alternative.
- Enhanced User Experience: With a one-week replacement schedule, the new lenses align with patients' time perceptions, significantly improving compliance and overall wearing experience, making it more convenient for daily use.
- Strategic Expansion: Scheduled for launch in Canada on February 2, 2026, PRECISION7 is the latest addition to Alcon's WaterInnovations portfolio, further solidifying Alcon's leadership in eye care and driving continued growth in global markets.
See More
Launch of PRECISION7 Contact Lenses in Canada
- Product Innovation: The PRECISION7 contact lens features the world's first ACTIV-FLO System, providing 16 hours of outstanding comfort and precise vision, ensuring excellent performance even on day 7, significantly enhancing user experience.
- Market Demand: While nearly 90% of eye care professionals believe daily disposable lenses are better for patients, over half of new patients still opt for reusable lenses; the launch of PRECISION7 addresses this market need by offering a more affordable option.
- Convenient Replacement: PRECISION7 allows patients to choose any day of the week to replace their lenses, simplifying the replacement schedule and aligning better with patients' lifestyles, thereby improving compliance and comfort.
- Strategic Expansion: The launch of PRECISION7 in Canada marks the latest advancement in Alcon's WaterInnovations portfolio, further solidifying its leadership position in the global eye care market, with expectations to drive sales growth and enhance brand influence.
See More
William Blair Initiates Coverage on Alcon Inc. with Market Perform Rating
- Market Perform Rating: William Blair initiated coverage on Alcon Inc. (NYSE: ALC) with a Market Perform rating on Friday, indicating a neutral outlook on the company's future performance and reflecting a cautious view on its current stock price.
- Growth Drivers: Over the past two years, Alcon has aggressively driven revenue growth through increased R&D spending and several acquisitions, with analysts noting a robust product pipeline despite the stock trading at a roughly 25% premium to historical levels.
- Equipment Market Opportunity: Alcon's equipment segment accounts for about 10% of sales, with the upcoming launches of the UNITY surgical platforms in 2025 and 2026 expected to be significant growth drivers, particularly as customers replace aging systems.
- Consumables Growth Outlook: Consumables are projected to accelerate to about 7% growth in 2026, up from 5% in 2025, primarily driven by the premium-priced UNITY consumables, which enhances Alcon's competitive position in the market.
See More
Alcon Inc. Completes $750 Million Share Repurchase Program
- Completion of Buyback: Alcon Inc. has successfully completed its $750 million share repurchase program initiated on April 1, 2025, acquiring a total of 9,301,877 shares, which represents 1.9% of the current share capital, thereby enhancing earnings per share and boosting shareholder confidence.
- Significant Buyback Amount: The total buyback volume reached CHF 602 million (approximately $750 million), reflecting the company's recognition of its intrinsic value and aiming to offset the dilutive effects of its equity incentive plans by reducing the number of outstanding shares.
- Enhancing Shareholder Value: The repurchased registered shares will be held in treasury, intended to counteract the dilution caused by equity incentive plans, thereby further enhancing the value and returns for existing shareholders.
- Global Leadership Position: As a global leader in eye care, Alcon serves over 260 million people annually, and the successful execution of this buyback program will further solidify its competitive advantage in the eye care market and drive future business growth.
See More
STAAR Surgical Board Restructuring with Broadwood Partners Joining
- Board Changes: Neal Bradsher and Richard LeBuhn from Broadwood Partners, along with Christopher Wang from Yunqi Capital, have joined STAAR Surgical's Board of Directors, aiming to enhance profitability and long-term value creation, indicating a strong focus on the company's future development.
- Executive Departures: The board restructuring sees the departure of Chair Elizabeth Yeu and CEO Stephen Farrell, who will remain until January 31, 2026, signaling a significant shift in the company's strategic direction.
- Stock Performance: STAAR shares are currently priced at $20.82, trading 10% below the 20-day simple moving average and 19% below the 100-day moving average, reflecting a bearish outlook with a 3.50% decline over the past 12 months.
- Analyst Ratings: STAAR Surgical holds a consensus Hold rating among analysts with an average price target of $31.42, suggesting that despite current pressures, developments from the new board members could influence future performance.
See More
Bullish Investment Thesis on Alcon Inc.
- Market Leadership: Alcon Inc. is the world's largest pure-play eye care device company, with its global vision care market share projected to increase from 11.7% in 2020 to 13.5% in 2024, showcasing its competitive edge in a $35 billion market and bolstering investor confidence.
- Profitability Enhancement: The Surgical segment generates approximately 60% of EBIT, leveraging strong brand leadership and high-margin consumables, with operating margins expected to rise to 20-25%, providing long-term visibility into future cash flows.
- Innovation Platform Rollout: The multi-year rollout of the new UNITY surgical platform aims to replace existing equipment and enhance hospital efficiency; despite execution risks, the market has yet to fully recognize its potential for a ~7% revenue CAGR.
- Investment Appeal: Although Alcon's stock price has depreciated by about 8.66% since last year, the valuation framework suggests a price range of $65 to $138 based on a 20x P/E multiple, indicating significant upside potential that has attracted interest from 41 hedge funds.
See More
Alcon Launches PRECISION7 Contact Lenses in Canada
- Product Innovation: The PRECISION7 contact lens features the world's first ACTIV-FLO system, providing up to 16 hours of comfort and clear vision even on day seven, thereby addressing the need for extended wear options in the market.
- Market Demand: While nearly 90% of eye care professionals believe daily disposables are better for patients, over half of new patients still opt for reusable lenses; the launch of PRECISION7 fills this gap by offering an affordable alternative.
- Enhanced User Experience: With a one-week replacement schedule, the new lenses align with patients' time perceptions, significantly improving compliance and overall wearing experience, making it more convenient for daily use.
- Strategic Expansion: Scheduled for launch in Canada on February 2, 2026, PRECISION7 is the latest addition to Alcon's WaterInnovations portfolio, further solidifying Alcon's leadership in eye care and driving continued growth in global markets.
See More
Launch of PRECISION7 Contact Lenses in Canada
- Product Innovation: The PRECISION7 contact lens features the world's first ACTIV-FLO System, providing 16 hours of outstanding comfort and precise vision, ensuring excellent performance even on day 7, significantly enhancing user experience.
- Market Demand: While nearly 90% of eye care professionals believe daily disposable lenses are better for patients, over half of new patients still opt for reusable lenses; the launch of PRECISION7 addresses this market need by offering a more affordable option.
- Convenient Replacement: PRECISION7 allows patients to choose any day of the week to replace their lenses, simplifying the replacement schedule and aligning better with patients' lifestyles, thereby improving compliance and comfort.
- Strategic Expansion: The launch of PRECISION7 in Canada marks the latest advancement in Alcon's WaterInnovations portfolio, further solidifying its leadership position in the global eye care market, with expectations to drive sales growth and enhance brand influence.
See More
William Blair Initiates Coverage on Alcon Inc. with Market Perform Rating
- Market Perform Rating: William Blair initiated coverage on Alcon Inc. (NYSE: ALC) with a Market Perform rating on Friday, indicating a neutral outlook on the company's future performance and reflecting a cautious view on its current stock price.
- Growth Drivers: Over the past two years, Alcon has aggressively driven revenue growth through increased R&D spending and several acquisitions, with analysts noting a robust product pipeline despite the stock trading at a roughly 25% premium to historical levels.
- Equipment Market Opportunity: Alcon's equipment segment accounts for about 10% of sales, with the upcoming launches of the UNITY surgical platforms in 2025 and 2026 expected to be significant growth drivers, particularly as customers replace aging systems.
- Consumables Growth Outlook: Consumables are projected to accelerate to about 7% growth in 2026, up from 5% in 2025, primarily driven by the premium-priced UNITY consumables, which enhances Alcon's competitive position in the market.
See More
Alcon Inc. Completes $750 Million Share Repurchase Program
- Completion of Buyback: Alcon Inc. has successfully completed its $750 million share repurchase program initiated on April 1, 2025, acquiring a total of 9,301,877 shares, which represents 1.9% of the current share capital, thereby enhancing earnings per share and boosting shareholder confidence.
- Significant Buyback Amount: The total buyback volume reached CHF 602 million (approximately $750 million), reflecting the company's recognition of its intrinsic value and aiming to offset the dilutive effects of its equity incentive plans by reducing the number of outstanding shares.
- Enhancing Shareholder Value: The repurchased registered shares will be held in treasury, intended to counteract the dilution caused by equity incentive plans, thereby further enhancing the value and returns for existing shareholders.
- Global Leadership Position: As a global leader in eye care, Alcon serves over 260 million people annually, and the successful execution of this buyback program will further solidify its competitive advantage in the eye care market and drive future business growth.
See More
STAAR Surgical Board Restructuring with Broadwood Partners Joining
- Board Changes: Neal Bradsher and Richard LeBuhn from Broadwood Partners, along with Christopher Wang from Yunqi Capital, have joined STAAR Surgical's Board of Directors, aiming to enhance profitability and long-term value creation, indicating a strong focus on the company's future development.
- Executive Departures: The board restructuring sees the departure of Chair Elizabeth Yeu and CEO Stephen Farrell, who will remain until January 31, 2026, signaling a significant shift in the company's strategic direction.
- Stock Performance: STAAR shares are currently priced at $20.82, trading 10% below the 20-day simple moving average and 19% below the 100-day moving average, reflecting a bearish outlook with a 3.50% decline over the past 12 months.
- Analyst Ratings: STAAR Surgical holds a consensus Hold rating among analysts with an average price target of $31.42, suggesting that despite current pressures, developments from the new board members could influence future performance.
See More
